Literature DB >> 10860878

Membrane fusion between retroviral particles: host-range extension and vaccine prospects.

S Sparacio1, U Zeilfelder, T Pfeiffer, T Henzler, V Bosch.   

Abstract

We have analyzed if different populations of retroviral particles carrying the viral and cellular receptors of membrane viruses, respectively, are able to specifically fuse with each other. Using the glycoprotein of human immunodeficiency virus type 1 and its cellular receptor complex, we demonstrate that interviral membrane fusion can, indeed, occur and that the resultant fused viral structures are able to infect cells and transduce a marker gene. On the one hand, these results have relevance for the development of vaccine strategies based on fusion-induced conformational epitopes on the viral glycoprotein. However, in addition to this potential practical application, the results obtained (which were extended to include analyses with the vesicular stomatitis virus G protein and its cellular receptor) have far-reaching implications for in vivo situations in which simultaneous infections with different membrane viruses can occur. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10860878     DOI: 10.1006/viro.2000.0294

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  3 in total

1.  Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry.

Authors:  Graham Simmons; Dhaval N Gosalia; Andrew J Rennekamp; Jacqueline D Reeves; Scott L Diamond; Paul Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-04       Impact factor: 11.205

2.  Nef enhances human immunodeficiency virus type 1 infectivity resulting from intervirion fusion: evidence supporting a role for Nef at the virion envelope.

Authors:  J Zhou; C Aiken
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  A hunter virus that targets both infected cells and HIV free virions: implications for therapy.

Authors:  Cody Greer; Gisela García-Ramos
Journal:  Theor Biol Med Model       Date:  2012-12-06       Impact factor: 2.432

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.